Non-Small Cell Lung Cancer Coverage from Every Angle

Edward B. Garon, MD, on Capmatinib in METex14-Mutated Advanced NSCLC: Expert Perspective

Posted: Wednesday, May 13, 2020

Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses implications of the GEOMETRY mono-1 trial, which suggest capmatinib is efficacious against brain metastases in patients with non–small cell lung cancer—a significant issue for this population—with a manageable toxicity profile.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.